Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women

Age and Ageing

Volumn 38, Issue 3, 2009, Pages 283-289

  Semba, Richard D ^a   Ferrucci, Luigi ^b   Sun, Kai ^a   Patel, Kushang V ^b   Guralnik, Jack M ^b   Fried, Linda P ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Columbia University ^*  (United States)

Author keywords

Advanced glycation end products; Anaemia; Elderly; Haemoglobin; Women

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN;

AGE; AGED; AMINO ACID BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; RISK FACTOR; SMOKING; UNITED STATES;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; BALTIMORE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; LYSINE; ODDS RATIO; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 65449149507     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afp011     Document Type: Article

References (30)

1. Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Curr Opin Hematol 2005; 12: 123-8.
2. Basta G, Schmidt AM, de Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
3. Ando K, Beppu M, Kikugawa K, Nagai R, Horiuchi S. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem Biophys Res Comm 1999; 258: 123-7.
4. Iwata H, Ukeda H, Maruyama T, Fujino T, Sawamura M. Effect of carbonyl compounds on red blood cells deformability. Biochem Biophy Res Commun 2004; 321: 700-6.
5. Wautier JL, Wautier MP, Schmidt AM et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742-6.
6. Thomas MC, Tsalamandris C, MacIsaac R et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004; 66: 1167-72.
7. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
8. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-9.
9. Negrean M, Stirban A, Stratmann B et al. Effects of low-and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-43.
10. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
11. Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-109.
12. Wautier JL, Zoukourian C, Chappey O et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyper-permeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
13. Guralnik JM, Fried LP, Simonsick EM, Kasper D, Lafferty ME. The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability. Bethesda, MD: National Institute on Aging. NIH Publication No. 95-4009, 1995.
14. Stabler SP, Allen RH, Fried LP et al. Racial differences in prevalence of cobalamin and folate deficiencies in disabled elderly women. Am J Clin Nutr 1999; 70: 911-9.
15. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-78.
16. Boehm BO, Schilling S, Rosinger S et al. Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004; 47: 1376-9.
17. Zhang X, Frischmann M, Kientsch-Engel R et al. Two immuno-chemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005; 43: 503-11.
18. Sakurai S, Yamamoto Y, Tamei H et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73: 158-65.
19. Semba RD, Ricks MO, Ferrucci L et al. Types of anemia and mortality among older disabled women living in the community: The Women's Health and Aging Study I. Aging Clin Exp Res 2007; 19: 259-64.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
21. Motomiya Y, Oyama N, Iwamoto H, Uchimura T, Maruyama I. N e-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Kidney Int 1998; 54: 1357-66.
22. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
23. Suliman ME, Heimbürger O, Bárány P et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614-22.
24. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Renal Physiol 2005; 289: F645-59.
25. Kalousová M, Hodková M, Kazderová M et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-11.
26. Uribarri J, Peppa M, Cai W et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003; 42: 532-8.
27. Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-33.
28. Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-70.
29. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, deGroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-5.
30. Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.